COVID-19

COVID-19 Update

As a leading global pharmaceutical company that provides essential medicines to millions of patients worldwide, we are continually assessing the impact of COVID-19 as it evolves each day.

As always, we remain committed to our patients, employees, partners, the quality and continuity of our products and the health and safety of our communities. Here are some of the steps we are taking:

Protecting Employee Health and Well-being

To ensure the health and safety of our employees we have implemented, and will continue to implement, measures to protect their well-being which in turn, will allow us to maintain continuity of supply.

Based on the guidance from global and local health authorities, we have instituted rigorous infection control measures within our facilities for those where work-from-home is not an option. Our measures include (but are not limited to): staggering employee shifts to reduce the size of work groups, modifying our cafeteria space to enhance social distancing, the implementation of additional cleaning and sanitization routines, robust self-assessment and screening tools, travel restrictions, a work-from-home policy and a strict visitor screening protocol.

We are recognizing employees who remain onsite with increased pay. It will begin retroactively to March 14th and continue until May 17th at which time we will revisit it again.

Prioritizing Our Supply Continuity

We play a critical role in ensuring millions of patients around the world have access to essential medicines. We are pursuing every step we can to minimize the disruption in drug supply and currently do not expect an impact on Apotex’s products.

As part of our regular business operations we have an active inventory management strategy and safety stock program, and we have enhanced this by increasing the reserves of our essential medicines. This includes inventory and safety stock for both active pharmaceutical ingredients (API) – the substance in medicines responsible for the beneficial health effects experienced by patients – as well as finished products. Our biosimilar portfolio, focused on oncology, is unaffected by the demand for API, and we do not foresee risks with these products. We are working closely with suppliers, monitoring for potential disruptions to our global supply chain.

In addition to securing supply for the short term, we maintain business continuity plans to address the longer-term needs of patients who depend on our products. We are continually assessing supply levels as well as product demand in order to make adjustments to our orders as well as manufacturing and distribution schedules as needed.

Additionally, we are the largest API producer in Canada, and this also helps to mitigate the risk.

Supporting the Community

Apotex has a long history of supporting communities around the world in times of need. This time is no different.

To date, we have made multiple donations of Hydroxychloroquine to clinical trials being conducted within Canada. Read more about one study focused on examining whether or not  hydroxychloroquine prevents infection of COVID-19 in front-line healthcare employees. We have also donated much needed medical supplies to affected areas.

Apotex donated two million dosages of hydroxychloroquine to the Canadian federal government for current and future COVID-19 related clinical trials and a portion will be used as part of National Emergency Strategic Stockpile. 

Researchers in Canada are encouraged to contact Apotex if they require supply of hydroxychloroquine for COVID-19 related clinical trials at hcqdonations@apotex.com.

We are using our technical expertise and manufacturing capability at our Apotex Pharmachem facility to produce and donate hand sanitizer in support of frontline workers in community agencies and healthcare facilities fighting COVID-19 within Ontario

We have donated thousands of N95 surgical masks for use by frontline healthcare employees working in community agencies and healthcare settings

We continue to review additional opportunities to support other communities around the world.

Continued Recruitment During COVID-19

We also know many people have been economically impacted due to this crisis. As a pharmaceutical company, millions of patients rely on us every day. Because of this, we have the tremendous responsibility to stay open and continue the work that we do. We have a wide range of open positions within the organization that we hope to fill even during these unprecedented times. Part of “Innovating for Patient Affordability” means being agile and putting you first. At this time, we are taking precautionary measures by adapting our recruitment strategy to ensure our staff and applicants are safe by conducting our interviews and onboarding online.

 

Last updated: 04/21/20